150 related articles for article (PubMed ID: 34488870)
1. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Derrett-Smith E; Clark KEN; Shiwen X; Abraham DJ; Hoyles RK; Lacombe O; Broqua P; Junien JL; Konstantinova I; Ong VH; Denton CP
Arthritis Res Ther; 2021 Sep; 23(1):234. PubMed ID: 34488870
[TBL] [Abstract][Full Text] [Related]
2. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
Avouac J; Konstantinova I; Guignabert C; Pezet S; Sadoine J; Guilbert T; Cauvet A; Tu L; Luccarini JM; Junien JL; Broqua P; Allanore Y
Ann Rheum Dis; 2017 Nov; 76(11):1931-1940. PubMed ID: 28801346
[TBL] [Abstract][Full Text] [Related]
3. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.
Hoyles RK; Khan K; Shiwen X; Howat SL; Lindahl GE; Leoni P; du Bois RM; Wells AU; Black CM; Abraham DJ; Denton CP
Arthritis Rheum; 2008 Apr; 58(4):1175-88. PubMed ID: 18383385
[TBL] [Abstract][Full Text] [Related]
5. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
6. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.
Derrett-Smith EC; Dooley A; Gilbane AJ; Trinder SL; Khan K; Baliga R; Holmes AM; Hobbs AJ; Abraham D; Denton CP
Arthritis Rheum; 2013 Nov; 65(11):2928-39. PubMed ID: 23839959
[TBL] [Abstract][Full Text] [Related]
7. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses.
Wei J; Zhu H; Komura K; Lord G; Tomcik M; Wang W; Doniparthi S; Tamaki Z; Hinchcliff M; Distler JH; Varga J
Ann Rheum Dis; 2014 Feb; 73(2):446-54. PubMed ID: 23515440
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM; Bedossa P; Ratziu V; Anstee QM; Bugianesi E; Sanyal AJ; Loomba R; Harrison SA; Balabanska R; Mateva L; Lanthier N; Alkhouri N; Moreno C; Schattenberg JM; Stefanova-Petrova D; Vonghia L; Rouzier R; Guillaume M; Hodge A; Romero-Gómez M; Huot-Marchand P; Baudin M; Richard MP; Abitbol JL; Broqua P; Junien JL; Abdelmalek MF;
N Engl J Med; 2021 Oct; 385(17):1547-1558. PubMed ID: 34670042
[TBL] [Abstract][Full Text] [Related]
9. Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.
Lucattelli M; Fineschi S; Selvi E; Garcia Gonzalez E; Bartalesi B; De Cunto G; Lorenzini S; Galeazzi M; Lungarella G
Respir Res; 2016 May; 17(1):49. PubMed ID: 27153807
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.
Wu M; Melichian DS; Chang E; Warner-Blankenship M; Ghosh AK; Varga J
Am J Pathol; 2009 Feb; 174(2):519-33. PubMed ID: 19147827
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.
Tsujino K; Reed NI; Atakilit A; Ren X; Sheppard D
Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L22-L31. PubMed ID: 27864286
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of bleomycin-induced pulmonary fibrosis via TGF-β-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells.
Hsu YA; Chang CY; Lan JL; Li JP; Lin HJ; Chen CS; Wan L; Liu FT
J Biomed Sci; 2020 Jan; 27(1):24. PubMed ID: 31937306
[TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.
Gonzalez EG; Selvi E; Balistreri E; Akhmetshina A; Palumbo K; Lorenzini S; Lazzerini PE; Montilli C; Capecchi PL; Lucattelli M; Baldi C; Gianchecchi E; Galeazzi M; Pasini FL; Distler JH
Ann Rheum Dis; 2012 Sep; 71(9):1545-51. PubMed ID: 22492781
[TBL] [Abstract][Full Text] [Related]
14. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A
Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649
[TBL] [Abstract][Full Text] [Related]
15. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.
Li LF; Kao KC; Liu YY; Lin CW; Chen NH; Lee CS; Wang CW; Yang CT
J Cell Mol Med; 2017 Nov; 21(11):2937-2949. PubMed ID: 28598023
[TBL] [Abstract][Full Text] [Related]
17. GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro.
Speca S; Dubuquoy C; Rousseaux C; Chavatte P; Desreumaux P; Spagnolo P
PLoS One; 2021; 16(9):e0257281. PubMed ID: 34529707
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.
Mutlu GM; Budinger GR; Wu M; Lam AP; Zirk A; Rivera S; Urich D; Chiarella SE; Go LH; Ghosh AK; Selman M; Pardo A; Varga J; Kamp DW; Chandel NS; Sznajder JI; Jain M
Thorax; 2012 Feb; 67(2):139-46. PubMed ID: 21921091
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
20. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
